The removal of larger uremic toxins by conventional dialysis membranes is restricted by their molecular weight cut-offs. The recent availability of a new generation of hemodialysis membranes with molecular weight cut-offs closer to that of the native kidney (65 kDa) has led to work assessing their potential utility across several different clinical scenarios. Initially designed to remove proinflammatory cytokines in patients with severe sepsis syndrome, clinicians are now using these membranes for the treatment of myeloma kidney and rhabdomyolysis. Further early pilot studies have demonstrated a potential utility for the removal of larger middle molecules in the population with end-stage renal failure. The purpose of this review was to summarize the current evidence base for the use of high cut-off hemodialysis membranes and discuss their future clinical relevance.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.